

# Claire T Deakin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5767165/publications.pdf>

Version: 2024-02-01

24  
papers

1,725  
citations

687220

13  
h-index

642610

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

4002  
citing authors

#	ARTICLE	IF	CITATIONS
1	Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature Communications, 2020, 11, 6317.	5.8	1,042
2	Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration. Frontiers in Immunology, 2018, 9, 3167.	2.2	87
3	Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis and Rheumatology, 2016, 68, 2806-2816.	2.9	83
4	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.5	81
5	CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon- $\gamma$ . Frontiers in Immunology, 2018, 9, 1372.	2.2	68
6	Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis and Rheumatology, 2019, 71, 1377-1390.	2.9	51
7	Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. Frontiers in Immunology, 2018, 9, 2951.	2.2	50
8	Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis and Rheumatology, 2018, 70, 785-793.	2.9	41
9	Accepting Risk in Clinical Research: Is the Gene Therapy Field Becoming Too Risk-averse?. Molecular Therapy, 2009, 17, 1842-1848.	3.7	37
10	Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Neuropathology and Applied Neurobiology, 2019, 45, 410-420.	1.8	36
11	Impact of next-generation sequencing error on analysis of barcoded plasmid libraries of known complexity and sequence. Nucleic Acids Research, 2014, 42, e129-e129.	6.5	31
12	Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Research and Therapy, 2020, 22, 79.	1.6	30
13	JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatric Rheumatology, 2021, 19, 146.	0.9	19
14	Limiting $\beta$ c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood, 2007, 110, 91-98.	0.6	13
15	Gene Therapy Researchers' Assessments Of Risks And Perceptions Of Risk Acceptability In Clinical Trials. Molecular Therapy, 2013, 21, 806-815.	3.7	10
16	Association with HLA-DR $\beta$ 1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	1.4	9
17	Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study. Arthritis Research and Therapy, 2018, 20, 180.	1.6	8
18	The ethics of gene therapy: balancing the risks. Current Opinion in Molecular Therapeutics, 2010, 12, 578-85.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Modelling disease activity in juvenile dermatomyositis: A Bayesian approach. <i>Statistical Methods in Medical Research</i> , 2019, 28, 35-49.	0.7	6
20	Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models. <i>Rheumatology</i> , 2021, 60, 1891-1901.	0.9	6
21	Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases. <i>Med</i> , 2021, 2, 1093-1109.e6.	2.2	6
22	A survey to understand the feelings towards and impact of COVID-19 on the households of juvenile dermatomyositis patients from a parent or carer perspective. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab058.	0.3	3
23	Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis. <i>Current Rheumatology Reports</i> , 2021, 23, 24.	2.1	1
24	An Integrative Analytical Approach to Subphenotyping of Juvenile Dermatomyositis. <i>Rheumatology</i> , 2015, , .	0.9	0